In NSCLC tumors, the EML4-ALK fusion is hypothesized to create an immunosuppressive TME by activation of downstream oncogenic signaling pathways leading to the activation of the PI3K, MAPK, and Hippo pathways [29,49] (Figure 2a). The gene discussed is ALK; the disease is non-small cell lung carcinoma.